Anaplastic Astrocytoma – Pipeline Review, 2020

Anaplastic astrocytoma is a rare malignant brain tumor. Astrocytomas develop from star-shaped brain cells called astrocytes. Astrocytomas are classified on the basis of the grading system provided by World Health Organization (WHO).  The grading system is designed on the basis of the size of the tumor. Anaplastic astrocytomas are grade III astrocytomas. Symptoms observed in the patients suffering from anaplastic astrocytomas include headaches, lethargy, vomiting, and changes mental status or personality. In rare cases, seizures, vision problems, weakness in the arms and legs resulting in coordination difficulties are also observed.

Current treatment for anaplastic astrocytoma includes radiation, surgery, and chemotherapy. Food and Drug Administration (FDA) has approved temozolomide (Temodar) for the treatment of adults with anaplastic astrocytoma.

Research Institutes and pharmaceutical companies have focussed on studying and developing new methods for the treatment of anaplastic astrocytoma. For instance; ADV/HSV-tk (gene therapy), which is being studied by the Methodist Hospital System, is currently in phase-2 clinical trials for the study of the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

To know how our report can help streamline your business, Speak to Analyst

Currently, more than 60% of the pipeline candidates for anaplastic astrocytoma are in the phase 1 clinical stage. Majority of the studies have been sponsored by research institutes and hospitals.

Report Description

The report on ‘Anaplastic Astrocytoma – Pipeline Review, 2020’ provides a comprehensive overview of the drugs that are in the R&D pipeline for anaplastic astrocytoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, and details such as sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for anaplastic astrocytoma.

The report on ‘Anaplastic Astrocytoma – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for anaplastic astrocytoma


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for anaplastic astrocytoma


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary